

New granted patents to score drug exposure on cells and tissues.

May, 24 2018
Billerica, MA & Lille, France

ImaBiotech is pleased to announce the grant of two patents in the USA **US9645138** and Europe **EP2959294** for a new technology that allows to score drug exposure to cells and tissues.

The imaging technology provides very accurate and quantitative information on drugs that either reach expected or unexpected targets at cellular levels. This technique can be used in drug discovery or development stages as well as in clinical trials. This new technology is used with a computational power in a computer vision and image analysis to provide a high throughput screen. It allows a selection of the best drugs based on their capacity to reach biological targets in animal or human tissues. For example, it enables to identify if the drug crosses the Blood Brain Barrier or reach specific T-cells in the tumor micro-environment.

According to Jonathan Stauber, CEO ImaBiotech, the technology has various applications. "We are very excited about this new technology, because for the first time, in one single experiment, we can quantify, if a drug binds to its target or to other targets throughout many therapeutic applications, such as CNS, Oncology, cardiovascular diseases."

The first applications of this technology will be presented at ASMS 2018 occurring in San Diego from June 3-7.

About ImaBiotech:

ImaBiotech is a Contract Research Organization (CRO) with two facilities locations: Boston (MA) and France. The company offers innovative services to the pharmaceutical research to provide better drug efficacy and toxicity evaluations from preclinical to clinical stages, making better and safer drugs.

Services are based on different imaging techniques related to Quantitative Mass Spectrometry, which is a technology developed and constantly improved by ImaBiotech. Quantitative Mass Spectrometry (QMSI) has been developed for decades and allows to effectively detect elements as well as molecules without labelling. ImaBiotech has developed the quantitative aspects through many patents making ImaBiotech the worldwide leader in this field. QMSI is a game changer in the pharmaceutical industry making it applicable to many therapeutic areas. While other techniques, this molecular technique brings deeper information about drug localization and its pharmacology effects to diseased tissues and damaged cells. This increases the interpretation of drug efficacy and toxicity improving drugs and improving time to market. Thanks to our patents, we've developed Quantinetix and Multimaging to interpret pharmacology in tissue.

Contact: Edma Fontaine / 0033 320 164 097 / contact@imabiotech.com